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Expression of Vascular Endothelial Growth Factor in PreImplantation Mouse Embryos

Abstract

Establishment of an adequate endometrial vascular supply is crucial for successful implantation
and development of mammalian embryos. Uterine endometrial receptivity determines the success of
implantation, as human embryos and gametes are routinely harvested, maintained and fertilized in vitro
in assisted reproduction. Once a viable embryo is transferred to a uterus, however, its chance of
establishing a pregnancy in the recipient female is only approximately 20%. Embryos placed in the
distal portion of the fallopian tube typically show a higher rate of pregancy success, thus suggesting that
embryo-derived factors may contribute to uterine receptivity.
Angiogenesis, the extensive development and growth of capillaries, is essential to the
establishment of the vascular network needed for maternal-fetal exchange through the placenta. Prior to
implantation, the endometrial vascular network is random and contains no specific orientation. Factors
released at the site of implantation cause the vessels to orient towards the developing embryo and
provide it with an ample blood supply. The factor(s) that directs blood vessel formation during
implantation is not known.
Vascular endothelial growth factor (VEGF) is specific to vascular endothelial cells and has
significant angiogenic and permeability effects. There are four main variants of VEGF that are due to
alternative exon splicing of a single mRNA strand. Two variants are cell-associated (206 and 189),
while two are soluble (165 and 121). There are no known functional differences between the variants.
Receptors for VEGF areftns-Iike tyrosine kinase (flt) and kinase domain-containing receptor (KDR).
They are predominantly expressed on endothelial cells, although the embryo may also contain receptors
on its trophoblast cells.
The purpose of this study was to determine if VEGF is expressed in the early preimplantation
mouse embryo. The uterus is known to make VEGF but it was not known if the preimplantation embryo
itself made VEGF or if it contained VEGF receptors. Mouse eggs and embryos were used because their
embryonic implantation is similar to human implantation. The availability of samples and ethics
concerns also made mouse specimens the viable choice.
RNA was extracted from the eggs/embryos then made into a complementary strand of DNA
(cDNA) by the process of reverse transcriptase. An oligo (dT) primer was used to differentiate mRNA
being actively translated, which contained poly A+ tails, from other mRNA in the sample. Once the
cDNA was obtained, it was amplified by polymerase chain reaction (PCR). Mouse kidney cDNA was
used for the positive control tissue as it was known to contain both VEGF and actin and was the same
tissue type as the samples. Actin was used as the control gene within the sample because it is highly
expressed in all cells. The primers used were expected to produce a 548 base pair fragment for actin, and
a 349 base pair fragment for VEGF that is common to all VEGF variants. To test for contamination, a
negative control containing only the stock reagents and ddH20 was also prepared. The PCR products
were loaded into non-denaturing polyacrylamide gels for electrophoresis analysis.
Both mouse eggs and blastocysts appear to express VEGF. It is difficult to envision a role for
VEGF in the egg stage, but it may be involved in early folliculogenesis. VEGF, if secreted by the
embryo, may flow down the fallopian tube and prime the uterus for implantation. When the blastocyst
begins to implant, VEGF may promote blood vessel redirection and growth at the implantation site. At
the blastocyst stage, VEGF may act as both a permeability and an angiogenic factor. A third function for
VEGF may also exist at this stage. The blastocyst produces VEGF and the trophoblast cells are believed
to contain VEGF receptors, therefore the blastocyst may induce its own growth.

Introduction

Establishment of an adequate endometrial vascular supply is crucial for successful
implantation and development of mammalian embryos. Uterine endometrial receptivity
determines the success of implantation, as human embryos and gametes are routinely harvested,
maintained and fertilized in vitro in assisted reproduction. Once a viable embryo is transferred to
a uterus, however, its chance of establishing a pregnancy in the recipient female is only
approximately 20%. Embryos placed in the distal portion of the fallopian tube typically show a
higher rate of pregnancy success, thus suggesting that embryo-derived factors may contribute to
uterine receptivity.
Angiogenesis, the extensive development and growth of capillaries, is essential to the
establishment of the vascular network needed for maternal-fetal exchange through the placenta.
It differs from vasculogenesis in that angiogenic growth occurs from pre-existing cells and
vessels rather than creating totally new ones. Prior to implantation, the endometrial vascular
network is random and contains no specific orientation. Factors released at the site of
implantation cause the vessels to orient towards the developing embryo and provide it with an
ample blood supply (Torry R and Rongish B, 1992). The factor(s) that directs blood vessel
formation during implantation is not known.
Vascular endothelial growth factor (VEGF) is specific to vascular endothelial cells and
has significant angiogenic and mitogenic effects (Ferrara N et a!., 1992). It has also been shown
to increase microvascular permeability and was originally named vascular permeability factor
(Brown Let a!., 1992). Preventing tumor angiogenesis has been the main focus of much recent
research involving VEGF, as tumors cannot survive if their blood supply is ceased. The role of

VEGF in reproduction is now being explored and its full involvement in that field is not yet
known.
There are four isoforms of VEGF that originate from alternative exon splicing of a single
mRNA strand (Ferrara et aI., 1992). There are thought to be no functional differences between
the four variants, but they do have significant biological differences. VEGF 206 and VEGF 189 are
cell-associated, meaning they only affect cells adjacent to cells that produce these variants. The
other two isoforms, VEGF l65 and VEGF I21 , are diffusable into the extracellular matrix. Thus, the
variant determines what cells VEGF acts on in relation to the cells that express it. If secreted by
the embryo, VEGF could contribute to local permeability and angiogenesis and/or prime the
uterus for implantation, depending on the variant( s) expressed.
Receptors for VEGF are thefms-like tyrosine kinase (fit) and kinase domain-containing
receptor (KDR). They are predominantly expressed on endothelial cells, although the embryo
may also contain receptors on its trophoblast cells (Charnock-Jones D et aI., 1994, Torry D et al.,
unpublished). Since VEGF is known to have mitogenic effects, if embryos secrete VEGF and
also contain receptors for it, they may use VEGF as a means to promote their own growth.
The purpose of this study was to determine if VEGF is expressed in the early
preimplantation mouse embryo. The uterus is known to make VEGF (Torry D et aI., 1995) but it
was not known if the preimplantation embryo itself makes VEGF or if it contains VEGF
receptors. Mouse eggs and embryos were used because their embryonic implantation is similar
to human implantation. The ready availability of samples and ethical concerns also made mouse
specimens the viable choice.

Materials and Methods

Mouse Kidney Samples
A whole mouse kidney was surgically removed from a sacrificed mouse and snap-frozen

in liquid nitrogen immediately upon removal. The kidney was stored at -80°C until used. GITC
solution was added and the kidney was ground with a tissue homogenizer. RNA was extracted
via the GITC method (see below).

MCF-7 Breast Cancer Cells
A T25 flask was grown to confluency and RNA was extracted via the GITC method
(see below).

Mouse Embryo Samples
The embryos used in these studies were collected at different stages of preimplantation
development (Hogan, et aI., 1986). Egg samples were collected by first priming the mice with
SID pregnant mare serum gonadotropin (PMSG). After 48 hours they were given human
chorionic gonadotropin (hCG) to induce superovulation. The oviducts were flushed with Hams
FlO culture media containing 1% Human Serum Albumin (HSA) 12 hours later to collect the
free eggs. Cumulus cells were removed by hyuronidase (lmg/10mL). Typically a final volume
of 2 microliters (J.1L) of media contained 10 eggs.
More advanced stages of embryonic development were collected after in vitro culturing
of fertilized eggs. The mice were induced to superovulate with SID of PMSG followed 48 hours
later with SID hCG. They were then placed in cages with proven fertile mates. The females

were sacrificed at day 1.5 post coitus (d 1.5 p.c.) and their oviducts were flushed to collect the
embryos at the 2 cell stage. A portion of the embryos were cultured under standard conditions
and samples were collected at the zona pellucida-free late blastocyst stage (d4.5 p.c.). The late
blastocyst stage corresponds to the time of implantation in vivo in mice. The GITC method was
predominantly used to extract RNA (see below), however the crude lysate method (see below)
was used when GITC failed to obtain enough RNA for amplification.

Extraction ofRibonucleic Acid (RNA) by the Guanidinium Isothiocynate (GITC) Method
To extract RNA from the samples, the cells were first lysed (Chomczynski and Sacchi,
1987). A lysing stock solution was made of 4M GITC (83.3g), 25 mM Na Citrate (pH=7,
5.87mL of .75M), 0.5% N-Iauroylsarcosine (8.8mL of 10%), and 97.67 mL
diethylpyrocarbonate treated water (DEPC H20). This stock solution was combined with
2-~-mercaptoethanol

(2-ME) in the following ratio to create a working solution: 14 J.lL 2-ME to

2mL of stock solution. 500J.lL of the working solution was added to the cell sample and the cells
were lysed on ice for 15 minutes.
After denaturization occurred, RNA was extracted from the eggs/embryos. The following
reagents were added in order on ice for 500J.lL of denaturing solution: 50J.lL 2M Na-acetate
(PH=4.0), 500J.lL phenol (H20 saturated, not buffered), and 100J.lL chloroformlisoamylalcohol
(24:1). The solution was mixed and kept on ice for 15 minutes, then centrifuged at 10,000 x g
for 20 minutes. The aqueous phase of the solution was removed and ImL of isopropanol was
added. The RNA was placed at -20°C to -80°C and allowed to precipitate overnight. The
precipitated solution was centrifuged at 10,000 x g for 20 minutes and the supernatants were
removed. The pellet was resuspended in 300J.lL GITC/2-ME (working solution) and 300J.lL

isopropanol was added. The solution was allowed to re-precipitate at -20°C to 80°C for at least
30 minutes. The precipitated solution was centrifuged at 10,000 x g for 15 minutes and the
supernatants were removed. The pellet was washed with 500flL 75% ethanollDEPC H 20
solution and centrifuged. The supernatants were again removed. The pellet was dried under
vacuum and then resuspended in DEPC H20 and IOU of RNasin. The optical density at 260
nanometers was taken to determine the RNA concentration of the solution according to the
formula: absorbance of 1.0 = 30flg/mL RNA.

Preparation ofRNA Using the Crude Lysate Method
In this method, all reactions took place in the crude lysates to avoid loss of RNA during
the purification process (Pal et al., 1994). Snap-frozen eggs/embryos were lysed by adding an
equal volume of 0.5% Nonidet-P 40 (NP-40), 10mM dithiothreitol (DTT), and IOU Rnasin. The
solution was reverse transcribed (see below) and run through a spin column to concentrate the
RNA and DNA. It was then dried under a vacuum, resuspended in 20flL double distilled water
(ddH20), and heated at 50°C to 60°C for 10 minutes.

Synthesis ofComplementary Deoxyribonucleic Acid (cDNA) by Reverse Transcriptase (RT)
Reaction
IOflg of RNA (usually in <5flL) were mixed with 10 pmol of oligo (dT)18 in a 0.5flL
RNA-safe Eppendorftube. The primer oligo (dT)18 was used to differentiate messenger RNA
(mRNA) being actively translated, which contain poly A+ tails, from non-translated mRNA.
The mixture was placed at 70°C for 2 minutes in a water bath and then slow cooled to 35°C. A
reverse transcriptase reagent mix consisting of 20U avian myeloblastosis virus reverse

transcriptase (AMV-RT), 4flL 5x AMV-RT buffer, IflL of each 10mM deoxyribonucleotide
triphosphate (A,C,G,T), 0.2flL 1M DTT, and 14U RNasin, was added to the RNA and
oligo(dT)]8' DEPC H20 was added to the mixture to make the final volume of the RT reaction
equaI20J..lL. The entire mixture was incubated at 42°C for two hours and then was placed for 2
minutes at 95°C to inactivate the RT. Afterwards it was chilled on ice for 1 minute and
centrifuged at maximum for a few seconds. The newly prepared cDNA was kept frozen and
stored at -20°C.

Amplification ofGenes Present in cDNA Sample by Polymerase Chain Reaction (PCR)
Under an isolation hood, a working stock solution of PCR reagents was prepared
proportionally to the number of samples tested. For each sample tube, 5 J..lL lOx PCR Buffer 1,
IJ..lL of each 10mM deoxribonucleotide triphosphate (A,C,G,T), 1 flL sense primer (100 pmol),
1 flL anti-sense primer (100 pmol), and 2.5U AmpliTaq®DNA Polymerase were added. The
primers for each gene were:
Actin sense

5'-CTC-CTT-AAT-GTC-ACG-CAC-GAT-TTC-3 ,

Actin anti-sense

5'-GTG-GGG-CGC-CCC-AGG-CAC-CA-3'

VEGF sense

5'-ATG-AAC-TTT-CTG-CTG-TCT-TGG-T-3 ,

VEGF anti-sense

5'-CTC-ATC-TCT-CCT-ATG-TGC-3'

These primers were expected to produce a 548 base pair fragment for actin and a 349 base pair
fragment for VEGF that is common to all VEGF isoforms.
Aliquots of 11.5flL of the stock solution were put into each PCR tube. 5J..lL of cDNA and
33.5J..lL ddH20 were added to the solution to make the final volume equal 50flL. In some cases
the amount of cDNA assayed was increased to raise sensitivity. Mouse kidney cDNA was used

for the positive control as it is known to contain both VEGF and actin (Brown et al., 1992). To
test for contamination, a negative control containing only the stock solution and 38.5~L ddH20
was also prepared. 55JlL of mineral oil was added to each sample tube and one drop of mineral
oil was placed into the wells of a Perkin-Elmer Model PCR thermal cycler. The tubes were
seated into the wells and the machine was set for 35 cycles for 1 minute each at 94°C, 61 °c, and
72°C. At the end of the cycles, the samples stayed at 72°C for 5 minutes and then went to a 4°C
hold until their removal. They were stored at -20°C until analyzed by gel electrophoresis. In
some cases heightened sensitivity was needed so a "nested PCR" was performed. Instead of
cDNA,

I~L

ofPCR product was added to 11.5JlL of stock solution and 37.5~L ddH20. The

tube was then placed in the thermal cycler and the machine was set for 25 cycles of the same
temperatures and durations as above.

Analyses of peR Products by Non-Denaturing Polyacrylamide Gel Electrophoresis
A 50/0 non-denaturing acrylamide gel solution was prepared using 2.0 mL 40% Acryl
Bisacryl, 1.6 mL lOx Tris (Hydroxymethyl) Aminomethane-Borate-Ethylenediaminetetraacetic
acid buffer (TBE), 12.4 mL ddH20, 20 JlL Tetramethyl-ethylenediamine (TEMED), and 100 J.1L
10% NH4 S02 • The solution was gently mixed so as not to introduce air bubbles and was poured
between two glass plates enclosed in a gel caster. A comb was placed at the top of the plates to
form wells for the samples. When solidified, the gel and the glass plates were removed from the
caster and clamped onto an electrophoresis unit. 1x TBE buffer was added to the top chamber
until it spilled over into the sample wells

(~

150 mL). 1x TBE buffer was also added to the

bottom tank chamber until it was approximately half full
5~L

of DNA sample loading buffer was added to

(~

250 mL).

20~L

aliquots of the PCR products and

to a 0.7 JlL aliquot of 123 base pair ladder molecular weight marker. The samples were loaded
into the sample wells using a long-nosed pipette tip.
The electrodes were attached to the electrophoresis unit and 100 volts of electricity was
applied until the bromophenol blue in the loading buffer ran off the bottom of the gel. The glass
plates containing the gel were unclamped from the unit and carefully pried apart. The gel and the
remaining glass plate were placed in a gel staining tray containing ddH20. The water released
the gel from the plate and the plate was removed. 3 JlL ethidium bromide (EtBr) was added to
the water. The gel was allowed to soak in the EtBr solution for 10 minutes with slow agitation to
stain the DNA bands on the gel for interpretation under UV light. For band clarity, the gel was
destained by draining the EtBr solution from the tray and adding fresh ddH20. The gel was then
photographed under UV light with a Polaroid MP-4 photography set using type 57 film.

Results

Expression of VEGF in MCF-7 Cells and Mouse Kidney
Preliminary tests were conducted on non-precious samples to test procedures and primers.
MCF -7 breast cancer cells show an overexpression of VEGF, as cancerous cells typically do
(Boocock C et aI., 1995). Since determining VEGF expression in a normal tissue was ultimately
the goal of these tests, mouse kidney was used as a comparison to the MCF -7 cells.
RNA was extracted via the GITC method and stored at -80°C until analyzed by RT-PCR.
The RNA concentration was 1.6 Jlg/JlL for MCF-7 and 4.2 Jlg/JlL for mouse kidney. 10Jlg of
RNA from each sample were reverse transcribed to produce 20JlL of cDNA. For PCR, 2.5JlL of
cDNA were taken from the MCF-7 sample to test for actin, and 5JlL ofcDNA were taken to test
for VEGF. The amounts of cDNA taken to test for actin and VEGF were the same for the mouse
kidney.
Through the use of non-denaturing polyacrylamide gel electrophoresis, the number of
base pairs in a sample were gauged against a 123 bp ladder molecular weight marker. In Fig. 1,
actin in MCF-7 cells produced a strong band at the predicted 548 bp level (lane 2). Mouse
kidney also expressed actin, as its band can clearly be seen at that level in lane 3. The expression.
of actin in these two samples shows that the RNA extraction, RT, and peR procedures were
successful and thus gives credence to the VEGF lanes. A 349 bp fragment, the size predicted for
VEGF, was detected for MCF-7 in lane 6 and for mouse kidney in lane 7. Both negative control
lanes were blank (lanes 4 and 8), indicating no contamination was present.

Expression of VEGF in Mouse Eggs, Cumulus Cells, Blastocysts, and Mouse Kidney
After several unsuccessful attempts to isolate an adequate amount of RNA from eggs
using the GITC method, it was determined that another method might yield more RNA. The
crude lysate method was then used to prepare RNA from 19 mouse eggs. IOU RNasin and IOflL
of the NP-40IDTT mix were added to the eggs to lyse them. After reverse transcription, 80flL of
cDNA were obtained from the eggs. 50JlL were removed and run through a spin column, dried
under a vacuum, and resuspended in 20JlL ddH20. For PCR, 10JlL of the concentrated cDNA
were used to test for actin, while the other 10JlL were used to test for the presence ofVEGF. In
order to increase sensitivity, a nested PCR was also performed for both actin and VEGF using
1flL of their respective PCR products to serve as a substitute for cDNA.
The RNA from cumulus cells, blastocysts, and kidney tissue were extracted using the
GITC method. The RNA concentration was 11.1 Jlg/JlL for cumulus cells, 2.3 flg/flL for
blastocysts, and 4.2flg/JlL for the mouse kidney. lOJlg of RNA from each sample were reverse
transcribed, producing 20flL of cDNA from each of them. 5JlL of both blastocyst cDNA and
cumulus cell cDNA were removed to test for actin. The same volume of each was also removed
to test for the presence ofVEGF. From the kidney cDNA, 2flL were removed to test for actin,
while 4JlL were removed to test for VEGF. Negative controls lacking cDNA were also prepared.
All of these samples produced a final PCR product volume of 50JlL after stock solutions and
primers were added.
The PCR products were analyzed by gel electrophoresis. The RT-PCR process
succeeded, as fig. 2 shows a 548 bp fragment of actin in the egg (lane 1), nested egg (lane 2),
blastocyst (lane 4), and mouse kidney (lane 7). However, it was not seen in cumulus cells (lane
4). VEGF appears to be expressed throughout embryonic development, as Fig. 3 shows the

predicted 349 bp fragment ofVEGF in the egg (lane 2), nested egg (lane 3), cumulus cells (lane
4) blastocysts (lane 5) and mouse kidney (lane 7). The negative controls (lane 6 in figs. 2 and
3) were both blank indicating no contamination was present.
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~VEGF

Fig. 1. Expression of actin and VEGF analyzed by RT-PCR. Ethidium bromide stained po1yacryJamide gel
showing actin in MCF-7 cells (lane 2), actin in mouse kidney (lane 3) VEGF in MCF-7 cells (lane6), VEGF in
mouse kidney (lane 7) and controls (no cDNA added lanes 4 and 8). Molecular weight markers (MW) are a 123
bp ladder. Sizes predicted for actin and VEGF were 548 and 349 bp respectively.
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Fig. 2. Expression of actin analyzed by RT-PCR. Ethidium bromide stained polyacrylamide gel showing actin in
eggs (lane 2), nested eggs (lane 3), blastocysts (lane 5), and mouse kidney (lane 7). No actin is evident in cumulus
cells (lane 4). The control (no cDNA added, lane 6) is negative for contamination. The molecular weight marker
(MW) is a 123 bp ladder. The predicted actin size was 548 bp.
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Fig. 3. Expression of VEGF analyzed by RT-PCR. Ethidium bromide stained polyacrylamide gel showing
YEGF in eggs (lane 2), nested eggs (lane 3), cumulus cells (lane 4), blastocysts (lane 5), and mouse kidney (lane 7).
The control (no cDNA added, lane 6) is negative for contamination . The molecular weight marker (MW) is a 123
bp ladder. The predicted YEGF size was 349 bp.

Discussion

By RT-PCR analysis, both mouse eggs and blastocysts appear to express VEGF. Since
the VEGF fragment produced by PCR is common to all four variants, it is impossible to
differentiate which variant(s) is being produced. Since cumulus cells are known to express
VEGF (fig. IB, Kamat Bet aI.., 1995), egg samples that are not totally cumulus-free may appear
to express VEGF when none is actually present. The egg samples tested in this study, however,
were visibly free of any cumulus cells. The crude lysate method of preparing the egg RNA may
also have contributed to the appearance of a VEGF band. The egg cDNA that was used was
heavily concentrated and PCR may have amplified a miniscule amount of VEGF message that is
not biologically relevant. It is believed, based on this study, that VEGF is expressed in the egg
although its role at that stage is not yet understood. One possibility for VEGF involvement at the
egg stage is in folliculogenesis. Future studies could compare equal volumes of cumulus-free
egg samples with cumulus-attached egg samples to determine the validity of VEGF expression.
At the blastocyst stage, VEGF may be important in implantation by initiating
reorientation of blood vessels and increasing vascular permeability. VEGF variants 121 and 165
are soluble and, if present in the embryo, could precede it and prime the uterus for implantation.
VEGF variants 189 and 206, if present, may influence local permeability and angiogenic events
at the implantation site. Therefore, VEGF may be necessary for successful implantation of the
embryo and for placental growth. Future studies could test for the individual variants of VEGF
in the blastocyst to determine which one(s) is expressed.
A possible additional function of VEGF besides angiogenesis and permeability may be
trophoblast growth promotion. Since trop~oblast cells are believed to contain VEGF receptors

(Charnock-Jones D et al., 1994, Torry D et al., unpublished) and the blastocyst was shown to
produce VEGF, the blastocyst may induce its own trophoblast growth.
The major source of VEGF within the blastocyst is not known, but it is likely to be the
trophoblast. Therefore, trophoblast production of VEGF could induce trophoblast receptors and
possibly promote both placental formation and trophoblast growth. In future studies, trophoblast
cells could be separated from the inner cell mass and tested individually for VEGF expression.
This would determine the exact location of VEGF secretion from the blastocyst.
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